Related Experiment Video
Updated: Aug 10, 2026
08:45
Polygraphic Recording Procedure for Measuring Sleep in Mice
Published on: January 26, 2016
[Development of compounds active in insomnia: recent developments and methodological aspects]
L Staner1, R Luthringer, J-P Macher
1Unité d'Exploration des Rythmes Veille-Sommeil et FORENAP, Centre Hospitalier de Rouffach, 27, rue du 4e RSM, 68250 Rouffach. luc.staner@forenap.asso.fr
Revue Neurologique
|December 4, 2003
Summary
New insomnia treatments aim for specific pathways, not global brain activity, to improve efficacy. Objective measures like polysomnography and EEG spectral analysis are crucial for evaluating drug effects and sleep quality.
Area of Science:
- Neuroscience
- Pharmacology
- Sleep Medicine
Context:
- Current insomnia pharmacotherapies broadly target GABAergic systems.
- This broad action may limit treatment efficacy and patient acceptance.
- There is a need for more targeted therapeutic approaches.
Purpose:
- To explore the development of novel molecules with specific activity pathways for insomnia.
- To outline essential criteria for evaluating hypnotic drug efficacy and tolerability.
- To emphasize the importance of objective sleep assessment methods.
Summary:
- Investigates developing insomnia pharmacotherapies with targeted mechanisms beyond global GABAergic activity.
- Highlights the necessity of both subjective and objective measures, including polysomnography and EEG spectral analysis, for efficacy assessment.
- Discusses evaluating residual effects using psychomotor, neurocognitive, and driving simulator tests in carefully selected patient cohorts.
Impact:
- Aims to improve treatment efficacy and acceptance for insomnia.
- Establishes a framework for rigorous clinical evaluation of new hypnotic agents.
- Contributes to advancing the understanding and treatment of insomnia through scientific rigor.
Related Concept Videos
01:14CNS Depressants: Barbiturates and Benzodiazepines
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
01:23Sedatives and Hypnotics: Overview
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
01:19Management of Insomnia
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
01:19Sedatives and Hypnotics Drugs: Benzodiazepines
Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:24Substance Use Disorders Affecting Sleep
Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
Understanding the concepts of physical dependence,...